Trusted Resources: People & Places
Online groups, photo galleries and blogs
Beverly L. Davidson, PhD
Raymond G. Perelman Center for
Cellular and Molecular Therapeutics
Children’s Hospital of Philadelphia
3401 Civic Center Blvd.
Philadelphia, Pennsylvania, United States
Beverly L. Davidson, PhD, is Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics and Chief Scientific Strategy Officer at Children’s Hospital of Philadelphia, where she holds the Arthur V. Meigs Chair in Pediatrics. She is also a Professor in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania and a Co-Founder of Spark Therapeutics, Inc., a biotechnology company CHOP created in 2013 to accelerate the timeline for bringing new gene therapies to market.
Beverly L. Davidson completed her PhD in Biological Chemistry, and Postdoctoral Fellowship from the University of Michigan, Ann Arbor, MI. Her research is focused on the development of novel therapies to treat inherited brain disorders. Dr. Davidson’s main research interest includes lysosomal storage diseases, mucopolysaccharidoses, spinal cerebellar ataxia, understanding how noncoding RNAs participate in neural development and neurodegenerative diseases processes, etc.
Klane K. White, MD, MScKlane K. White, MD, MSc is a Pediatric O...
Treatment of Skeletal and Non-Skeletal Alterations of Mucopolysaccharidosis Type IVA by AAV-Mediated Gene TherapyMucopolysaccharidosis type IVA (MPSIVA) ...
Walla Al-Hertani, MD, MS, FRCPC, FCCMG, FACMGDr. Walla Al-Hertani is a Medical Bioche...
Long-Term Safety and Clinical Outcomes of Intrathecal Heparan-N-Sulfatase in Patients With Sanfilippo Syndrome Type ...Currently, there is no effective therapy...
Julie Eisengart, PhD, LPDr. Julie Eisengart is an Associate Prof...
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) From Abeona ...Ultragenyx Pharmaceutical Inc. and Abeon...
Intracerebral Gene Therapy in Four Children With Sanfilippo B Syndrome: 5.5-Year Follow-Up ResultsWe report the safety (primary endpoint) ...